u/SecondPrevious7385

Author argues MAIA is an asymmetric setup: an ~$80M market cap company whose first-in-class telomere-targeting drug ateganosine produced 17.8-month median overall survival in 22 heavily pretreated third-line NSCLC patients versus ~5-6 month historical chemotherapy benchmarks, plus 90.5% disease control in the initial Phase 2 expansion cohort. The randomized 300-patient Phase 3 THIO-104 trial (ateganosine plus Regeneron's Libtayo vs investigator-selected chemo) is underway with interim survival data expected in 2027, and FDA Fast Track plus clinical-supply relationships with Regeneron, Roche and BeOne support the program. Main risks include the small non-randomized Phase 2 sample, potential failure to reproduce the signal in Phase 3, no revenue, and significant dilution from warrants, options and a $150M shelf.